Jessica D'alessandro
Adult Health · Amherst, NYNPI 1538754106
Payments from drug & device makers
Across 471 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$983
- GSK$819
- Novo Nordisk$778
- AbbVie$758
- Amgen$505
- plus $4K from 34 others
What the payments were for
- Food & beverage$9,06199%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $1,021 |
| Lilly USA, LLC | 60 | $983 |
| GSK | 59 | $819 |
| Novo Nordisk | 46 | $778 |
| AbbVie | 26 | $758 |
| Amgen | 26 | $505 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $444 |
| Boehringer Ingelheim | 25 | $408 |
| Gilead | 20 | $382 |
| E.r. Squibb & Sons, L.L.C. | 11 | $320 |
| Exact Sciences | 11 | $244 |
| Abbott | 10 | $192 |
| Pfizer | 9 | $180 |
| Esperion Therapeutics, Inc. | 6 | $175 |
| Johnson & Johnson | 12 | $164 |
| Endologix LLC | 1 | $162 |
| Astellas Pharma US Inc | 9 | $161 |
| Novartis | 8 | $154 |
| Bayer | 8 | $154 |
| Amarin Pharma, Inc. | 10 | $154 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $149 |
| Merck | 8 | $134 |
| Shield Therapeutics Inc | 7 | $119 |
| Otsuka America Pharmaceutical, Inc. | 6 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $65 |
| Sanofi-aventis U.S. LLC | 3 | $63 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Eisai Inc. | 2 | $33 |
| Covis Pharma GmbH | 2 | $32 |
| Vertex | 1 | $28 |
| Verona Pharma, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Insulet Corporation | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| Advanced Oxygen Therapy Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$366
- Alto Abdominal Stent Graft System$162
- ELIQUIS$125
- NURTEC ODT$125
- Ozempic$125
- FARXIGA$125
- Repatha$125
- BREZTRI$112
- NEXLIZET$112
- NEXLETOL$112
How this compares
$9,175 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 21 | $26,947 |
| EliquisApixaban | 38 | $24,142 |
| RybelsusSemaglutide | 24 | $23,425 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $20,597 |
| FarxigaDapagliflozin Propanediol | 32 | $20,245 |
| OzempicSemaglutide | 13 | $20,243 |
| JardianceEmpagliflozin | 13 | $16,599 |
| MounjaroTirzepatide | 13 | $15,777 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $13,021 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $8,363 |
| VascepaIcosapent Ethyl | 23 | $8,147 |
| Icosapent Ethyl | 25 | $7,046 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,676 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,551 |
| Levothyroxine Sodium | 88 | $1,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $778 | $43,66837 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $983 | $42,72434 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $408 | $24,96326 claims |
| PfizerEliquis | $180 | $24,14238 claims |
| GSKTrelegy Ellipta | $819 | $20,59717 claims |
| AstraZenecaFarxiga | $1,021 | $20,24532 claims |
| MerckJanumet Xr | $134 | $13,02111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in Amherst
- Katelyn McCormackAmherst$201K
- Michelle GillilandAmherst$25K
- Carly HarringtonAmherst$24K
- Clarice HartAmherst$16K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.